New Recruiting Trial: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
WHY IT MATTERS
This is now actively recruiting children with growth hormone deficiency — families interested in potentially accessing LUM-201 before FDA approval should check eligibility requirements and contact the trial sites listed on ClinicalTrials.gov.
Lumos Pharma is testing a new drug called LUM-201 in children who don't produce enough growth hormone naturally. This Phase 3 trial is the final stage of testing before the drug might be approved by the FDA. Researchers are actively recruiting children to participate and see if this treatment helps them grow taller.
NCT ID: NCT06948214 Title: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency Status: RECRUITING Phase: PHASE3 Sponsor: Lumos Pharma Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT06948214 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If your child has been diagnosed with growth hormone deficiency, visit clinicaltrials.gov/study/NCT06948214 to find nearby trial sites and learn about enrollment requirements.